Dr. Reddy's to Release Q1 FY14 Results on July 30, 2013

Updated

Dr. Reddy's to Release Q1 FY14 Results on July 30, 2013

Earnings call slated for July 30, 6.30 PM IST / 9.00 AM EDT*

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories (NYS: RDY) will announce results for the First Quarter ended June 30, 2013 on Tuesday, July 30, 2013 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.

Summary of Events

Event

Date and Time (IST)

Medium

Release of financial results

July 30th, after the Board Meeting

Email, Media, Company website, Business Wire

Earnings Call

July 30th, 6.30 PM IST / 9:00 AM EDT

Hosted by the Company
(Details below)

Webcast of Earnings Call

July 30th, 6.30 PM IST / 9.00 AM EDT through August 4th, 2013

URL available on Company's website,

www.drreddys.com

Transcripts of the Earnings call

Will be available on the Company's website

URL available on Company's website, www.drreddys.com


Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company's financial performance.

Conference Dial-In Numbers

Primary Number:

+91 22 6629 0356

Secondary Number:

+91 22 3065 0136

The numbers listed above are universally accessible from all networks and all countries.

Local Access Number:

6000 1221
Available in - Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada
Accessible from all major carriers except BSNL/MTNL.
3940 3977
Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune
Accessible from all carriers.

USA: 1 866 746 2133

International Toll Free Number:

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through August 4th, 2013. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company's website.

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (NYS: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.

For more information, log on to: www.drreddys.com

*EDT- Eastern Daylight Saving Time



Investor Relations:
Dr. Reddy's Laboratories
Kedar Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak Savla, +91 40 49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 9082034931
mkalawadia@drreddys.com

KEYWORDS: United States Asia Pacific North America New York India

INDUSTRY KEYWORDS:

The article Dr. Reddy's to Release Q1 FY14 Results on July 30, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement